The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Evolving challenges in hepatic fibrosis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320530 · Cited by 2,649
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Self-citationCastéra, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M., Darriet, M., Couzigou, P., & de Lédinghen, V. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.018 · Cited by 2,487
Sampling Variability of Liver Fibrosis in Chronic Hepatitis C
Bedossa, P., Dargère, D., & Paradis, V. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.022 · Cited by 2,376
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
Regev, A., Berho, M. E., Jeffers, L. J., Milikowski, C., Molina, E. G., Pyrsopoulos, N., Feng, Z.-Z., Reddy, K. R., & Schiff, E. R. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04396-4 · Cited by 2,093
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Cited by
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Self-citationRecent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
TGF-β in progression of liver disease
Dooley, S., & ten Dijke, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1246-y · Cited by 718
“it is initiated by apoptosis and senescence as orchestrated biological processes to eliminate fibrogenic cells (Friedman 2010; 2008).”
BackgroundAnti-Inflammatory Action and Mechanisms of Resveratrol
Meng, T., Xiao, D., Muhammed, A., Deng, J., Chen, L., & He, J. (2021) · Molecules · doi:10.3390/molecules26010229 · Cited by 698
Wnt–β-catenin signalling in liver development, health and disease
Perugorria, M. J., Olaizola, P., Labiano, I., Esparza-Baquer, A., Marzioni, M., Marin, J. J. G., Bujanda, L., & Banales, J. M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0075-9 · Cited by 605
Evolving therapies for liver fibrosis
Schuppan, D., & Kim, Y. O. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66028 · Cited by 595
Interleukin-33-Dependent Innate Lymphoid Cells Mediate Hepatic Fibrosis
Mchedlidze, T., Waldner, M., Zopf, S., Walker, J., Rankin, A. L., Schuchmann, M., Voehringer, D., McKenzie, A. N. J., Neurath, M. F., Pflanz, S., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.018 · Cited by 502
The adverse outcome pathway concept: A pragmatic tool in toxicology
Vinken, M. (2013) · Toxicology · doi:10.1016/j.tox.2013.08.011 · Cited by 467
Clinical evidence for the regression of liver fibrosis
Ellis, E. L., & Mann, D. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.024 · Cited by 411
D'Ambrosio, R., Aghemo, A., Rumi, M. G., Ronchi, G., Donato, M. F., Paradis, V., Colombo, M., & Bedossa, P. (2012) · Hepatology · doi:10.1002/hep.25606 · Cited by 409
An, P., Wei, L.-L., Zhao, S., Sverdlov, D. Y., Vaid, K. A., Miyamoto, M., Kuramitsu, K., Lai, M., & Popov, Y. V. (2020) · Nature Communications · doi:10.1038/s41467-020-16092-0 · Cited by 319
Cell and tissue engineering for liver disease
Bhatia, S. N., Underhill, G. H., Zaret, K. S., & Fox, I. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3005975 · Cited by 309
Barron, L., & Wynn, T. A. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00414.2010 · Cited by 304
The myofibroblast in wound healing and fibrosis: answered and unanswered questions
Bochaton-Piallat, M.-L., Gabbiani, G., & Hinz, B. (2016) · F1000Research · doi:10.12688/f1000research.8190.1 · Cited by 293
Chronic Liver Injury Induces Conversion of Biliary Epithelial Cells into Hepatocytes
Deng, X., Zhang, X., Li, W., Feng, R.-X., Li, L., Yi, G.-R., Zhang, X.-N., Yin, C., Yu, H.-Y., Zhang, J.-P., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.022 · Cited by 289
Ogawa, T., Enomoto, M., Fujii, H., Sekiya, Y., Yoshizato, K., Ikeda, K., & Kawada, N. (2012) · Gut · doi:10.1136/gutjnl-2011-300717 · Cited by 253
Verbeke, L., Mannaerts, I., Schierwagen, R., Govaere, O., Klein, S., Vander Elst, I., Windmolders, P., Farre, R., Wenes, M., Mazzone, M., et al. (2016) · Scientific Reports · doi:10.1038/srep33453 · Cited by 236
Drug targeting to the diseased liver
Poelstra, K., Prakash, J., & Beljaars, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.011 · Cited by 172
“Effective antifibrotic drugs are not available, despite the numerous antifibrotic compounds that have been tested in animals and patients [82,83].”
BackgroundZhang, X.-W., Zhou, J.-C., Peng, D., Hua, F., Li, K., Yu, J.-J., Lv, X.-X., Cui, B., Liu, S.-S., Yu, J.-M., et al. (2020) · Autophagy · doi:10.1080/15548627.2019.1635383 · Cited by 166
Liver regeneration requires Yap1-TGFβ-dependent epithelial-mesenchymal transition in hepatocytes
Oh, S.-H., Swiderska-Syn, M., Jewell, M. L., Premont, R. T., & Diehl, A. M. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.008 · Cited by 148
Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage
Perugorria, M. J., Esparza-Baquer, A., Oakley, F., Labiano, I., Korosec, A., Jais, A., Mann, J., Tiniakos, D., Santos-Laso, A., Arbelaiz, A., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-314107 · Cited by 144
Spaceflight Activates Lipotoxic Pathways in Mouse Liver
Jonscher, K. R., Alfonso-Garcia, A., Suhalim, J. L., Orlicky, D. J., Potma, E. O., Ferguson, V. L., Bouxsein, M. L., Bateman, T. A., Stodieck, L. S., Levi, M., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152877 · Cited by 108
Borkham-Kamphorst, E., Schaffrath, C., Van de Leur, E., Haas, U., Tihaa, L., Meurer, S. K., Nevzorova, Y. A., Liedtke, C., & Weiskirchen, R. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.01.023 · Cited by 105
Review article: the reversibility of cirrhosis
Sohrabpour, A. A., Mohamadnejad, M., & Malekzadeh, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12044 · Cited by 80
LOXL2—A New Target in Antifibrogenic Therapy?
Puente, A., Fortea, J. I., Cabezas, J., Arias Loste, M. T., Iruzubieta, P., Llerena, S., Huelin, P., Fábrega, E., & Crespo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071634 · Cited by 79
“Phagocytosis of apoptotic hepatocytes by myofibroblasts triggers their fibrogenic activation via NADPH oxidase 2 (NOX2) and the JAK/STAT and PI3K/Akt pathways [13].”
BackgroundInfluentialMyocardin related transcription factor A programs epigenetic activation of hepatic stellate cells
Tian, W., Hao, C., Fan, Z., Weng, X., Qin, H., Wu, X., Fang, M., Chen, Q., Shen, A., & Xu, Y. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.029 · Cited by 73
Resident mesenchymal cells and fibrosis
Hutchison, N., Fligny, C., & Duffield, J. S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.015 · Cited by 51
“These stromal cells still displayed PDGFRβ on their surface, in accordance with a pericyte origin.”
BackgroundInfluentialKatsumata, L. W., Miyajima, A., & Itoh, T. (2017) · Hepatology Communications · doi:10.1002/hep4.1023 · Cited by 38
Insulin‐like growth factor binding protein‐related protein 1 contributes to hepatic fibrogenesis
Guo, X. H., Liu, L. X., Zhang, H. Y., Zhang, Q. Q., Li, Y., Tian, X. X., & Qiu, Z. H. (2014) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12126 · Cited by 39
Shao, M., Zhang, X., Sun, J., Dong, H., Han, X., Yang, Q., Chen, R., Shen, L., Xu, L., Wang, L., et al. (2025) · Exploration · doi:10.1002/exp.70000 · Cited by 26
“HSCs can be activated by many factors, including soluble stimuli (reactive oxygen species, LPS, and apoptotic bodies) and paracrine stimuli (secreted by Kupffer cells, sinusoidal endothelium, and hepatocytes) [7].”
Lu, N., Liu, Y., Tang, A., Chen, L., Miao, D., & Yuan, X. (2015) · BioMed Research International · doi:10.1155/2015/794862 · Cited by 21
Muthiah, M. D., Huang, D. Q., Zhou, L., Jumat, N. H., Choolani, M., Chan, J. K. Y., Wee, A., Lim, S. G., & Dan, Y.-Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-51189-7 · Cited by 15
Che, T., Yang, X., Zhang, Y., Zheng, Y., Zhang, Y., Zhang, X., & Wu, Z. (2024) · Small · doi:10.1002/smll.202400413 · Cited by 8
Metadata
- Authors
- Friedman, S. L.
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2010-06-29
- Volume
- 7
- Issue
- 8
- Pages
- 425-436
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W2057095258
- Cited by
- 581
- References
- 153
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.